Company news

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) news

Lixte Biotechnology Holdings, Inc. news releases on 6ix. Latest, Jul 6, 2026: LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin…

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) news

Press releases & updates

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

LIXTE Joins Russell Microcap Index

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships

LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year

LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership

Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming

LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline

LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research

LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment

LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.

LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

LIXTE Biotechnology Holdings Provides Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100